Stauderman Kenneth A.

CSO Kenneth Stauderman sold 1,000 shares at $3.65, bought 1,000 shares at $3.96 at unprofitable CALC; cluster buy signal amid +164.3% 30-day rally

Kenneth Stauderman, Chief Scientific Officer at CalciMedica, executed 2 separate transactions within 3 days: a sale of 1,000 shares on 2025-07-25 for $3,650.00 followed by a purchase of 1,000 shares on 2025-07-28 for $3,960.00, leaving him with 12,944 shares post-transaction. The filing is noteworthy because it occurs within a 14-day window in which 3 other insiders also purchased shares—a cluster buy pattern. However, context is important: the company posted net income of $-5,042,000.00 and remains unprofitable over its most recent full fiscal year. The stock has surged +164.3% over 30 days and currently trades at $3.78, down -28.7% from its 52-week high of $5.30. Stauderman's repurchase at $3.96 came after a sale at $3.65, suggesting a net-zero hedge rather than a conviction-driven accumulation move; the contemporaneous cluster activity across the executive team warrants investor monitoring of whether this reflects material non-public developments or simply reactive positioning in a highly volatile micro-cap equity.

Chief Scientific Officer Kenneth A. Stauderman bought 1,000 shares at $1.85 on 2025-07-01; cluster pattern with 2 other insider buys in 14 days as stock trades -70.2% from 52-week high.

Stauderman's inaugural purchase of 1,000 shares at $1.85 represents his first equity stake in CalciMedica, arriving as the stock has declined sharply to -70.2% from its 52-week high of $5.30 and trades near its 52-week low of $1.43. The company reported negative net income of $-5.0M and carries a market cap of $22.1M, indicating a pre-revenue or early-stage biotech profile typical of development-stage enterprises. Notably, 2 other insiders purchased within the same 14-day window, creating a cluster buy pattern that warrants monitoring given the distressed valuation context and the unprofitable financial state. This initial insider acquisition at depressed price levels merits investor attention to understand whether management's buying reflects a specific catalyst or risk assessment of current valuation.